RFA-AI-20-079: Human Immunology Project Consortium (U19 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants of up to $1.5 million to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make $16.0 million in total. Applications closed on June 4, 2021.
From the official notice on Grants.gov, last changed February 8, 2021. Checked November 7, 2026.
- Award ceiling$1.5 million
- Total funding$16.0 million
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU19
- Clinical trialsOptional
- Funded byNIAID
- Median yearly award$326,265
- Typical project length7.5 years
- U19, Research Program Cooperative Agreement. Several related projects under one award, with substantial NIH involvement. Other open U19 notices.
Projects funded under RFA-AI-20-079 were run by National Institute of Allergy and Infectious Diseases (NIAID, 8 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-AI-20-079 in the NIH Guide.
Key dates
| Posted | February 8, 2021 |
|---|---|
| Deadline | June 4, 2021 |
| Archived by Grants.gov | July 10, 2021 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $326,265; it allows up to $1.5 million per award.
- Most of the program's money (67% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Funding Opportunity Announcement (FOA) for the Human Immunology Project Consortium (HIPC) solicits applications from single institutions, or consortia of institutions, to participate in a network of human immunology profiling research groups in the area of infectious diseases, including HIV. The purpose of this FOA is to characterize human immune responses/mechanisms elicited by vaccinations, vaccine adjuvants or natural infections by capitalizing on recent advances in immune profiling technologies. Studies supported under this FOA will measure the diversity and commonalities of human immune responses under a variety of conditions and longitudinally using high-throughput systems immunology approaches coupled with detailed clinical phenotyping in well-characterized human cohorts. The resulting data will be used to develop molecular signatures that define immune response profiles and identify biomarkers that correlate with the outcomes of vaccinations, vaccine adjuvants or natural infections in humans. An additional goal of this program is to promote rapid public access to HIPC-supported data and meta-data through public portals such as ImmPort. A companion FOA will support development and operation of a HIPC Coordinating Center that will be responsible for fostering collaborations amongst HIPC-funded investigators; facilitating public dissemination of integrated HIPC findings and knowledge; and supporting development or adoption of new, robust methods for data integration, analysis, presentation, and visualization to further research and development in this field.
Funded under RFA-AI-20-079 so far
NIH funded 8 projects under RFA-AI-20-079 in fiscal 2022 to 2026, at 8 institutions. The median yearly award was $326,265.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| HIPC U19 Adaptive Immunophenotyping Core | Benaroya Research Inst at Virginia Mason | 2026 | $328,547 |
| Administrative Core | La Jolla Institute for Immunology | 2026 | $328,279 |
| Core-002 | Columbia University Health Sciences | 2026 | $171,812 |
| Human Immune Monitoring Core | Stanford University | 2026 | $137,479 |
| Scientific Project 1: Malaria Immune Responses to Pre-erythrocytic Malaria Vaccination or Infection | Seattle Children's Hospital | 2026 | $300,000 |
| Multi-omic immune profiling | Yale University | 2026 | $394,186 |
| Clinical Core | Icahn School of Medicine at Mount Sinai | 2026 | $207,418 |
| MOMI Data Management | Massachusetts Institute of Technology | 2026 | $435,680 |
Who has won Allergy and Infectious Diseases Research grants before
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Washington | 85 | $938 million |
| Duke University | North Carolina | 230 | $781 million |
| University of California, Los Angeles | California | 138 | $745 million |
| The Johns Hopkins University | Maryland | 321 | $668 million |
| Emory University | Georgia | 282 | $650 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-AI-20-079 still open?
No. It closed on June 4, 2021.
Who can apply for Human Immunology Project Consortium (U19 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Human Immunology Project Consortium (U19 Clinical Trial Optional)?
Closed June 4, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $1.5 million each. About $16.0 million in total.
Who has been funded under RFA-AI-20-079?
NIH RePORTER lists 8 projects funded under RFA-AI-20-079 in fiscal 2022 to 2026, at 8 institutions. The most were at Benaroya Research Inst at Virginia Mason, La Jolla Institute for Immunology, Columbia University Health Sciences.
Who has won Allergy and Infectious Diseases Research grants before?
The largest recipients over five fiscal years were Fred Hutchinson Cancer Center, Duke University, University of California, Los Angeles. The program made 13,282 awards worth $22 billion in that time.
Similar open grants
- Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)
- Limited Competition: NIMHD Initiative for Improving American Indian and Alaska Native Cancer Outcomes (U19 - Clinical Trial Optional)
- Systems Biology of Infection and Inflammation in Chronic Diseases (U19 Clinical Trial Not Allowed)
- Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Research Program (U19 Clinical Trial Optional)
- National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)